Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Utah Medical Products (UTMD) Work In Process (2016 - 2024)

Historic Work In Process for Utah Medical Products (UTMD) over the last 14 years, with Q4 2024 value amounting to $1.4 million.

  • Utah Medical Products' Work In Process fell 592.15% to $1.4 million in Q4 2024 from the same period last year, while for Dec 2024 it was $1.4 million, marking a year-over-year decrease of 592.15%. This contributed to the annual value of $1.4 million for FY2024, which is 592.15% down from last year.
  • According to the latest figures from Q4 2024, Utah Medical Products' Work In Process is $1.4 million, which was down 592.15% from $1.4 million recorded in Q3 2024.
  • Utah Medical Products' 5-year Work In Process high stood at $1.7 million for Q3 2023, and its period low was $1.1 million during Q2 2020.
  • For the 5-year period, Utah Medical Products' Work In Process averaged around $1.4 million, with its median value being $1.4 million (2020).
  • Examining YoY changes over the last 5 years, Utah Medical Products' Work In Process showed a top increase of 3822.53% in 2022 and a maximum decrease of 1466.38% in 2022.
  • Quarter analysis of 5 years shows Utah Medical Products' Work In Process stood at $1.4 million in 2020, then rose by 1.67% to $1.4 million in 2021, then decreased by 14.66% to $1.2 million in 2022, then rose by 25.98% to $1.5 million in 2023, then dropped by 5.92% to $1.4 million in 2024.
  • Its Work In Process was $1.4 million in Q4 2024, compared to $1.4 million in Q3 2024 and $1.4 million in Q2 2024.